Botulinum toxin A for the treatment of cervical dystonia.
Idiopathic cervical dystonia (ICD) is the most common adult-onset focal dystonia. It is characterised by relatively sustained, involuntary contractions of neck muscles. Injections of botulinum toxin (BTX)-A are safe and effective for the treatment of ICD, and have substantially improved its treatment. BTX-A is manufactured by Allergan Pharmaceuticals in the US and Ireland, and is distributed as Botox. In Europe, BTX-A is manufactured and distributed by Ipsen Pharmaceuticals as Dysport. Success rates for BTX-A injections for ICD ranges 64-90%, with 76-93% of injected patients experiencing pain reduction. Side effects are generally mild and include dysphagia and neck weakness.
University of South Florida, Parkinson's disease and Movement Disorders Center, 4 Columbia Drive, Suite 410, Tampa, Florida 33606, USA.
Theresa A
TA
Zesiewicz
William
W
Stamey
Kelly L
KL
Sullivan
Robert A
RA
Hauser
D000328:Adult; D000906:Antibodies; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D006801:Humans; D014103:Torticollis / Q000188:drug therapy*
D000906:Antibodies; D019274:Botulinum Toxins, Type A